To see the role of Navak Guggulu and Kanchnar Guggulu orally in Medoja Granthi (Lipoma)

Evaluation of Navak Guggulu and Kanchnar Guggulu in Medoja Granthi (Lipoma)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/08/035761

Enrollment

Registered

2021-08-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D17- Benign lipomatous neoplasm

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patient willing to participate in clinical study. Patient not taking any other medicines for Medoja granthi. Site - Anywhere on the body Size- between 1-75cc (volume) Number- 1 to 5 in numbers.

Exclusion criteria

Exclusion criteria: Patient having Medoja Granthi with inflammation and hyperpigmentation. Infected lipoma, calcified lipoma, Ulcerated lipoma, Malignant change(liposarcoma). Intolerance to therapy. Patients who are suffering from any other systemic disorders. During clinical trial, if a patient develops any serious conditions which requires urgent treatment. Pregnant women and lactating mothers. If a patient his/herself wants to withdraw from the clinical trial.

Design outcomes

Primary

Measure	Time frame
Subjective Parameters- Pain Site Objective Parameters- Size NumberTimepoint: 1 month	—

Secondary

Measure	Time frame
Subjective Parameters- Pain Site Objective Parameters- Size NumberTimepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Kainat Ansari

Patanjali Bhartiya Ayurvigyan Evam Anusandhan sansthan, Haridwar

manishakardam@gmail.com9027569585

Outcome results